Predictors of treatment response to adjunctive vagus nerve stimulation in difficult-to-treat depression: a retrospective data analysis

Treiber Michael[1,2], Baune Bernhard[3], Gramser Anna[1,2], Saelens Johan[1,2], Grüll Natalia[1,2], Rössler Karl[2,4], Novak Klaus[2,4], Thanarajah Sharmili Edwin[5], Reif-Leonhard Christine[5], Kavakbasi Erhan[3,6], Kraus Christoph[1,2]

[1] Department of Psychiatry and Psychotherapy, Medical University of Vienna

[2] Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna

[3] Department of Psychiatry, University Hospital Münster, University of Münster, Münster, Germany

[4] Department of Neurosurgery, Medical University of Vienna

[5] Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt - Goethe University Frankfurt, Frankfurt am Main, Germany

[6] Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Aachen, Germany

Abstract

Background: Difficult-to-treat-Depression (DTD) is a highly prevalent and burdening mental illness. Approximately 25% of patients are considered as treatment-refractory. Vagus nerve stimulation (VNS) has been suggested a promising add-on treatment for these individuals. Still, a large proportion of patients treated with VNS lack sufficient response. Further knowledge of the pathogenesis of depression and predictive biomarkers are needed to improve treatment options, including the choice for VNS. QTc length has been suggested as a predictive marker for VNS treatment response. We aim to validate these findings and to identify physiological and haematological markers that might predict response to VNS treatment.

Methods: We retrospectively analysed a subsample of the ongoing RESTORE-LIFE study. Prior to VNS treatment, baseline QTc length, and baseline serum blood samples were analysed and associated with the severity (Montgomery-Åsperg Depression Rating Scale (MADRS)) and the prospective course (six-, and 12-months follow-up) of depression after VNS initiation. We performed linear multiple regression analyses and correlation analysis with a stepwise forward approach.

Results: Data from 53 patients with DTD were included in this retrospective analysis. In a linear multiple regression analysis, taking age, sex and body-mass-index (BMI) into account, QTc length did

not predict MADRS scores after six-, and 12-months VNS, respectively. An exploratory stepwise linear multiple regression with a forward approach using hematological and sociodemographic variables as predictors identified four factors as the most relevant for depressive symptom reduction after six months VNS. Lower absolute neutrophil count, lower BMI, younger age, and higher low-density lipoprotein concentrations at baseline predicted a depressive MADRS score reduction after six-months VNS. Only absolute neutrophil count predicted symptom reduction after 12-months VNS.

Discussion: We could not replicate previous findings suggesting the QTc as a predictive marker of VNS treatment response. However, our findings suggest a significant association between absolute neutrophil count, BMI, and serum low-density lipoprotein and reduction of depression severity in individuals treated with VNS adjunctive to treatment as usual. However, further prospective studies are needed to validate these findings and clarify the underlying mechanisms. Such studies will provide a basis for personalized interventions in individuals with DTD.

Keywords

Vagus nerve stimulation, difficult-to-treat-depression, treatment response, precision psychiatry

Background

Major depressive disorder (MDD) is a heterogenous and complex disorder that is accompanied by high burden with a significant impact on social and daily functioning, and an increased suicidal risk (Bergfeld et al., 2018). An early remission has been identified as a crucial goal of treatment, as it has been associated with an improved outcome (Rush et al., 2006). Approximately one fourth of individuals with MDD fail to archive remission after multiple treatment trials and develop a chronic course of the disease. Thus difficult-to-treat depression (DTD) has been conceptualized, which is characterised by increased morbidity and mortality, increased relapse and suicide rates, increased rates of hospitalisations with a higher burden for mental and physical health services costs (Amos et al., 2018; Bergfeld et al., 2018; McAllister-Williams et al., 2020; Rush et al., 2006).

Vagus nerve stimulation (VNS) is an implantable neuromodulatory technique that has been suggested a long-term treatment option individuals with difficult-to-treat depression (DTD), either in unipolar or bipolar affective disorders. VNS may be used as an adjunctive treatment in individuals with DTD who did not achieve or sustain response to a minimum of four treatment trials including, psychopharmacological treatments, psychotherapies, and electroconvulsive therapy (Demyttenaere et al., 2024). A large-scale registry reported a reduction of depressive symptomatology of about 50% in approximately one third of patients within the first year of VNS adjunctive to treatment as usual (Aaronson et al., 2017). The RECOVER-trial, a large-scale randomized-controlled trial, investigating the effect of active VNS compared to sham-treatment, has been conducted in the US. Conway et al

(2025) revealed a high disease burden with extensive and unsuccessful exposure to antidepressant treatment in individuals with DTD who received VNS (Conway, Aaronson, Sackeim, Duffy, et al., 2024). While the study did not achieve the primary endpoint, a significant difference in depressive symptoms reduction, as assessed by the MADRS (observer rating; (Conway, Aaronson, Sackeim, George, et al., 2024)), VNS significantly improved secondary outcomes, such as quality of life, psychosocial functioning, and depression self-rating scores (Conway, Aaronson, Sackeim, George, et al., 2024; Rush et al., 2024). The RESTORE-LIFE study (ClinicalTrials.govNCT03320304) is an ongoing, global, prospective, multi-center, naturalistic, observational study evaluating the long-term effectiveness and safety of adjunctive VNS in individuals with DTD. In this study sample, older age and increased symptom severity has been related to increased symptom reduction after twelve months of VNS treatment (Kavakbasi et al., 2025).

The corrected QT interval (QTc), an indirect marker of the sympathovagal balance, has been suggested a biomarker of treatment response to antidepressant VNS (Longpré-Poirier et al., 2020). The authors investigated the association between QTc length and VNS treatment response in 19 patients suffering from MDD. They suggested that longer QTc prior to VNS may predict a greater reduction in depressive symptoms 12 to 24 months after VNS. However, relevant covariates such as sex were not taken into account in this analysis (Jayanthi et al., 2021). To date, no other predictive markers have been reported. Taken together, little is known about which biomarkers could predict a response to VNS treatment. To address this question, the central aim of this study was to replicate previous predictive properties of QTc time in an independent sample and to identify further blood-based biomarkers obtained prior to VNS in order to better select patients potentially improving of implanted VNS treatment.

Methods

Study sample

Patients included in this retrospective data-analysis were also taking part in the ongoing RESTORE-LIFE study. A detailed description of the RESTORE study protocol and procedures has been published elsewhere (Young et al. 2020). In this study, we included patients suffering from DTD recruited at three sites (Frankfurt, Münster, Vienna). Individuals 18 years of age or older were eligible if they met criteria for a primary diagnosis of recurrent or chronic major depressive episode (unipolar or bipolar) according to the *Diagnostic and Statistical Manual of Mental Disorders* (5th edition), who did not achieve treatment response to an adequate number of antidepressant treatment trials. Diagnosis was made based on the Mini-International Neuropsychiatric Interview. Exclusion criteria were (1) severe substance use disorder, (2) predominant psychosis, (3) severe personality disorder, and (4) mental retardation (Young et al 2020). The study was conducted in accordance with the Declaration of

Helsinki. All study procedures were approved by the Ethics Committees of the Medical University of Vienna, Münster and Frankfurt.

VNS treatment

After the decision for VNS as an adjunctive treatment in DTD was made by the psychiatrist, eligibility criteria were evaluated, and, if fulfilled, informed consent was obtained. The baseline assessment was conducted within six weeks to one week prior to VNS implant performed at the respective department of neurosurgery. In scheduled titration visits, stimulation titration was performed by a psychiatrist. Output current, pulse width, frequency, ON/OFF time were set during the titration visits. Taking safety and tolerability into account, the output current has been increased in steps of 0.25mA, with the possibility of several steps increasement in one titration visit. Default frequency and pulse width was set at 20Hz, and 250msec, respectively, and could have been adjusted by clinicians' choice. In default mode ON/OFF-time was set at 30sec, and 5min, respectively. To increase the duty cycle of VNS, the OFF-time could have been decreased. Treatment as usual, including psychotherapy, pharmacotherapy, and neuromodulation were continued due to clinical judgement.

Depressive symptoms - Montgomery–Åsberg Depression Rating Scale (MARDS)

The MADRS was performed at baseline and every three months by trained raters, who were aware of the details of the trial. Remission was *a priori* defined as a total score ≤ 9. Response was a prior defined as remission or a symptom reduction of 50% (Rush et al., 2024).

Electrocardiogram measurements

As a part of routine procedures, we obtained a 12-lead standard electrocardiogram (ECG) recorded on a CardiofaxM ECG-1350 (Nihon Kohden), ChiroMed MAC 1600 (GE Healthcare), or Hellige Cardiognost EK 56 (CAmed Medical System) at a speed of 25mm/s and gain of 10mm/mV prior to neurosurgical implantation of the VNS-device. For each patient 12-lead standard ECG was recorded after a 15min in supine relaxed position. Patients were instructed to breath normally, and to avoid talking or moving. Heart rate (HR) was calculated from the RR-Interval. To obtain QTc-mean, QT-intervals were corrected for heart rate for the entire ECG using Bazett's formula ($QTc = QT/\sqrt{RR}$ interval), the most widely used formular in clinical and research practises (C Bazett, 1997). Following the American Heart Association criteria QTc prolongation was defined as >460ms in women and >450ms in men (Giudicessi et al., 2019). All ECG-recordings were reviewed by two experienced physicians.

Hematological measurements

For this study, blood-based measures were available from the site in Vienna, thus we report explorative results from 22 patients. As a part of routine procedures before surgery, venous blood samples were obtained from patients between 7:00am and 8:00 am the day prior to surgical procedures. Patients were instructed to overnight fasting and tobacco abstinence for more that twelve hours prior to blood sample collection. Blood samples were processed immediately to the laboratory for analyses of white blood cells, i.e., eosinophils, neutrophils, lymphocytes, monocytes, platelets, platelet distribution width, mean platelet volume and derived ratios, as well as liver function tests, renal function tests, electrolytes, ferritin, and metabolic parameters, such as fasting blood glucose, total cholesterol, serum triglyceride (TG; reference range 50-200mg/dL), serum high-density-lipoprotein (HDL; reference range for standard risk 45-65mg/dL for women, 35-55mg/dL for men), serum low-density-lipoprotein (LDL; desirable for individuals without cardiovascular risk <150mg/dL). We further calculated inflammatory parameters, such as neutrophil to lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), NLR and monocyte-lymphocyte ratio (MLR), and the systemic inflammatory index (SII, (Šagud et al., 2023)).

Anthropometric measurements

Anthropometric assessments included height, weight, and body mass index. Height was recorded to the nearest of 0.1 cm. For weight measure patients were asked to remove their shoes, any heavy clothing (sweaters, jackets, or coats), and empty their pockets. Weight was measured to the nearest 0.1 kg. Body mass index was calculated as a ratio between weight and height (kg/m^2).

Statistical analysis

All statistical analysis were conducted with R statistical software version 4.3.2. Variables that did not follow a normal distribution, as indicated by Shapiro-Wilk test, were log-transformed. We utilized the original data for data description, and took transformed values for statistical analysis. We performed a correlation analysis to evaluate the association between MARDS score reduction and QTc length to relate our data to the previously published study by Longpré-Poirier et al., who included X patients in their study. We then tested whether QTc could predict MADRS score reduction after six- and 12-months VNS in a multiple regression analysis with age, BMI, sex, and MADRS baseline score as possible confounders. In accordance with several studies investigating the effect of VNS in MDD, we chose the 12-months outcome, expecting the larges effect size (Conway, Aaronson, Sackeim, George, et al., 2024; Kavakbasi et al., 2025; Kavakbasi & Baune, 2024; Lespérance et al., 2024; Longpré-Poirier et al., 2020; Rush et al., 2024). We chose six-months follow up in order to evaluate mid-term outcome. It has been reported that psychopharmacological interventions could be tapered at this timepoint, indicating a response to VNS.

We further conducted an exploratory analysis to test associations between MADRS score changes between six- and 12-months follow-ups and: baseline levels of inflammatory biomarkers, baseline levels of metabolic biomarkers and baseline BMI. For the exploratory analysis we first performed correlation analyses to evaluate associations between MADRS score reduction and: age, sex, BMI, MADRS baseline score, absolute Neutrophil count (ANC), Lymphocyte count, Monocyte count, Eosinophil count, Basophil count, Platelet count, NLR, MLR, PLR, SII, TG, HDL, LDL, CHOL, HbA1C, GLU, TSH. This part of the analysis was purely exploratory; thus, we did not apply a method for multiple comparisons. We considered a p-value smaller than 0.05 as statistically significant. Then, we conducted stepwise multiple linear regression models with a forward approach. We used the change in MADRS scores as the dependent variable, and the following variables and independent variables: sex, age, absolute Neutrophil count (ANC), Lymphocyte count, Monocyte count, Eosinophil count, Basophil count, Platelet count, NLR, MLR, PLR, SII, TG, HDL, LDL, CHOL, HbA1C, GLU, TSH. We considered a p-value smaller than 0.05 as statistically significant. The same strategy was replicated to explore associations between MADRS-score changes and baseline biomarkers at six- and twelve-months follow-up.

Results

Table 1 – sociodemographic and clinical characteristics of the total sample

Mean age at time of implantation (SD), years	51.2 (11.6)
Female, %	67.9 %
BMI	*30.1 (6.9)*
HR	76.9 (13.4)
QTc	428ms (26.8ms)
Baseline MADRS	30.1 (9.1)
3 months MADRS	21.2 (9.1)
6 months MADRS	19.4 (10.2)
9 months MADRS	19.9 (9.9)
12 months MADRS	17.7 (9.5)
6 months response rate, %	32.7 % (16 out of 49)
12 months response rate, %	37.0 % (17 out of 46)

Note: BMI = body mass index; HR = heart rate; MADRS = Montgomery-Åsberg Depression Rating Scale; QTc = Bazett corrected QT interval; numbers in () represent standard deviation

Sociodemographic and clinical characteristics

In total, 53 patients with DTD who received VNS were included in this study. Sociodemographic and clinical characteristics are summarized in table 1. The mean age was 51.2 (+- 11.6), 36 were female.

For five individuals ECG and BMI measurements were missing. Thus, 49 of the patients included completed most of the study-procedures. Of those, some did not attend follow-up visits. Accordingly, we included data from 45 individuals for the six-months and nine-months follow-ups, and data from 42 individuals for the twelve-months follow-up. Average MADRS-scores were 30.1 (+- 9.1), 21.2 (+- 9.1), 19.4 (+-10.2), 19.9 (+- 9.9), and 17.7 (+- 9.5) at baseline, three-, six-, nine-, and 12 follow-ups, respectively. At supine position, the averaged heart rate was 76.9 (+- 13.4) beats per minute (bpm), and Bazett QTc interval was 428ms +- 26.8ms. Ten individuals, six females and four males, showed prolonged QTc intervals at baseline.

Response rates were 32.7%, and 37.0% at six- and twelve-months follow-up, respectively. Of note, in one patient baseline MADRS score was 10 (i.e. almost in remission) who worsened, in two individuals <9 (8 and 9) therefore in remission, one worsened, one improved.

QTc and depressive symptoms score

Figure 1 - scatter plot for correlation between QTc length and MADRS-score reduction at six-months follow-up

Note: MADRS = Montgomery-Åsberg Depression Rating Scale; QTc = Bazett corrected QT interval; *R = pearson's correlation coefficient; f = female; m = male*

Pearson's correlation analysis revealed a significant association between QTc length and MADRS-score reduction, at six-months (r = -.34, p = .026; figure 1), but not at twelve-months follow-up. Taking age, sex, and BMI into account in our linear multiple regression analysis, QTc did not predict MADRS score reduction after six- (p = .189), and 12-months (p = .587), VNS, respectively.

Hematological markers and depressive symptoms score

We conducted exploratory correlation analyses (see table 3) which showed that improvement after six-months was more pronounced in patients with higher MADRS scores at baseline (p < .001).

After 12 months we observed that improvement in depressive symptoms was more pronounced in those with higher MADRS scores as baseline (p < .001), lower ANC (p = .020), lower NLR (p = .017), and lower SII (p = .017; table 3).

Table 3 - Exploratory analyses of the associations between changes in MADRS-scores after six-, and 12-months VNS and sociodemographic, clinical, and biological markers

	6 months follow-up			12 months follow-up		
	Pearson's rho	t	p	Pearson's rho	t	p
Age (baseline)	-0.036		0.807	-0.038		0.802
Sex (female vs male)		1.430	0.162		1.717	0.094
BMI (baseline)	-0.072		0.649	-0.017		0.915
MADRS baseline	0.524		**<0.001**	0.615		**<0.001**
ANC	-0.451		0.060	-0.527		**0.020**
Lymphocyte count	0.273		0.259	0.255		0.278
Basophil count	0.154		0.528	0.207		0.528
Eosinophil count	0.277		0.349	0.277		0.382
Monocyte count	-0.043		0.863	-0.224		0.344
Platelet count	-0.128		0.601	-0.165		0.488
NLR	-0.430		0.075	-0.540		**0.017**
MLR	-0.175		0.473	-0.258		0.273
PLR	-0.230		0.344	-0.235		0.318
SII	-0.432		0.074	-0.540		**0.017**
Glucose	-0.026		0.915	-0.005		0.982
TG	0.192		0.461	0.123		0.626
HDL	0.079		0.764	0.179		0.508
LDL	0.291		0.258	0.252		0.346
CHOL	0.244		0.345	0.134		0.597

Note: ANC = absolute neurophil count; BMI = body mass index; CHOL = total cholesterol; HDL = high-density-lipoprotein; HR = heart rate; LDL = low-density lipoprotein; MADRS = Montgomery-Åsberg Depression Rating Scale; MLR = monocyte

We generated a stepwise regression with a forward selection approach to determine the main contributions of hematological and anthropometric markers to MADRS scores reduction. As shown in table 4 the model for MADRS score reduction after six-months was significant (F=5.28, p=0.013, R^2=0.66). The results indicate that improvement in depressive symptoms severity after six-months VNS was associated with baseline lower ANC, and BMI, younger age, and higher LDL concentrations. At 12-months follow up improvement in depressive symptoms was associated with baseline lower ANC (F=6.55, p=0.020, R^2=0.28). Thus, ANC predicted improvement in depressive symptoms at both time point.

Table 4 – stepwise multiple regression models for MADRS score reduction with hematological and sociodemographic variables as predictors

Dependent variable	Independent variable	Beta	*p*
Six-months MADRS score reduction	ANC	-0.005	0.020
	LDL	0.169	0.031
	Age	-0.499	0.039
	BMI	-1-140	0.007
12-months MARDS score reduction	ANC	-0.004	0.020

Note: : ANC = absolute neurophil count; BMI = body mass index; LDL = low-density lipoprotein; MADRS = Montgomery-Åsberg Depression Rating Scale;

Discussion

In this retrospective data analysis, we tested the association between baseline QTc length and depressive symptoms reduction in the course in patients suffering from DTD who received VNS adjunctive to treatment as usual. Against our hypothesis and a previously published study by others we could not demonstrate that QTc length predicts response to antidepressant VNS treatment. In additional exploratory analysis we identified four significant independent factors: absolute neutrophil count, BMI, age, and LDL that may serve as potential markers to predict depressive symptoms reduction due to VNS as an add on treatment in DTD. Of note, in our sample response rates to VNS were relatively small compared to previous investigation from other sites (Lespérance et al., 2024; Longpré-Poirier et al., 2020; Pigato et al., 2023; X. Zhang et al., 2022). However, our response rate is similar to the reports from the RECOVER-trial (Rush et al., 2024).

In our sample, we did not find evidence for an association between baseline QTc length and depressive symptoms reduction after six- and twelve-months VNS, respectively. This is contrary to findings Longpré-Poirier et al. (2020), who reported that increased QTc length at baseline was associated with a greater reduction in depressive symptoms after 12 and 24-months antidepressant VNS as assessed using the Hamilton-Depression-Rating-Scale (Longpré-Poirier et al., 2020). Contrary

to these findings, we found a trend wise association between shorter baseline QTc length and increased depressive symptoms reduction in female individuals with DTD. This is in line with other investigations indicating that an increase in QTc length may be linked to a predominance of the parasympathetic activity while shortened QTc length indicates a predominance of the sympathetic activity (I. Singh & Rabkin, 2021). There is growing evidence that depressive symptomatology is associated with dysfunctions in the autonomic nervous system (Jandackova et al., 2016; Moretta & Messerotti Benvenuti, 2022; Watanabe et al., 2024). For instance, altered heart rate variability, a marker of autonomic function, has been associated with a vulnerability to depression independent from antidepressant medication use (Jandackova et al., 2016; Moretta & Messerotti Benvenuti, 2022). Yet, we could not demonstrate an association between QTc length and depressive symptoms severity, thus a more direct marker of the autonomic nervous system, such as the HRV might be investigated in future antidepressant VNS studies. Differences between females and males in the indices of depressive symptoms associated with alterations in the sympathovagal balance have been suggested (Jandackova et al., 2016; Kuang et al., 2019).

Regarding the exploratiory analysis we observed a significant association between ANC, BMI, and LDL with greater improvement in depressive symptoms severity. Our results align with prior reports suggesting a relationship between immune-metabolic (immunological and metabolic) parameters and treatment response ins MDD (Elbakary et al., 2025; Karageorgiou et al., 2023; Wagner et al., 2019). We found that lower ANC concentration at baseline was associated with increased improvement in depressive symptoms after antidepressant VNS. A growing body of evidence supports the notion of Inflammation as a major factor in the pathogenesis and the course of MDD (Karageorgiou et al., 2023; Kofod et al., 2022; Osimo et al., 2019; Sforzini et al., 2025). Notably, an association between ANC and depressive symptoms has been reported (Elbakary et al., 2025; Guo et al., 2024; D. Singh et al., 2022). Elevated ANC has been associated with increased risk for depression (Foley et al., 2023). Whereas in MDD, lower ANC has been related to treatment response (Elbakary et al., 2025). Several studies suggested markers of low-grade inflammation, such as NLR, MLR, PLR, and SII as potential markers involved in the pathogenesis and the course of depression (Chen et al., 2025; Elbakary et al., 2025; Foley et al., 2023; Ninla-aesong et al., 2024; Xue et al., 2025; Zheng et al., 2024). For example, a decrease in NLR has been observed after antidepressant medication use which was linked to an improvement in cognitive function (Xue et al., 2025). However, a decrease in NLR was not related to an overall depressive symptom's improvement (Elbakary et al., 2025; Xue et al., 2025). PLR has been suggested a marker of treatment response to SSRIs, indicating that higher PLR values were associated with increased risk for treatment resistance (Elbakary et al., 2025; Ninla-aesong et al., 2024). In our sample we could not identify a predictive value for such markers regarding response to VNS. This may reflect differences in mechanism of action between antidepressant medication and VNS, the heterogeneity of depression, sample size, and methodological procedures.

Prior studies showed an effect of VNS on the inflammatory system in MDD (Corcoran et al., 2005; Kavakbasi et al., 2024; Lespérance et al., 2024). One study showed increases in both, pro- and anti-inflammatory cytokines over the course of three-months VNS (Corcoran et al., 2005). Whereas Kavakbasi et al. (2024) demonstrated an anti-inflammatory effect of VNS in individuals with treatment resistant depression after twelve-months VNS (Kavakbasi et al., 2024). Another study supports these findings with anti-inflammatory effects after four years of VNS (Lespérance et al., 2024). These findings underscore the role of inflammation in MDD and its associations with the autonomic nervous system. Yet, none of the studies mentioned related the observed alterations in inflammatory cytokines to depressive symptoms improvement (Corcoran et al., 2005; Kavakbasi et al., 2024; Lespérance et al., 2024). Changes in ANC or other markers of inflammation, such ss NLR, PLR and SII have not been investigated. This remains to be elucidated. Taken together, such low-grad-inflammation may be involved in the pathogenesis of MDD, however, inflammatory markers may not correlate with treatment response. Further research is needed to clarity the associations between inflammatory pathways and treatment outcomes in MDD.

Further we found an association between higher LDL levels at baseline and improvement of depressive symptoms severity after VNS. Disturbances in the cholesterol metabolism have been linked to MDD. Thus, cholesterol metabolites have been indicated as predictors for response to antidepressant treatment. However, Data regarding the association between circulating serum lipoprotein levels and depression are controversial. A meta-analysis reported a cross-sectional association between low-serum LDL levels and depression (Persons & Fiedorowicz, 2016). Crucially, a prospective study found that LDL levels were higher in individuals with a current major depressive episode compared to the healthy controls. In this study, LDL levels were positively associated with depressive symptoms severity. Notably, higher baseline LDL levels were associated with a stronger decline in symptom severity after treatment initiation (Wagner et al., 2019). Noteworthy, antidepressant treatment, such as electroconvulsive therapy and antidepressant medication have been reported to alter circulating cholesterol levels (Gabriel, 2007; Hummel et al., 2011). An increase in total cholesterol, HDL, and LDL has been found following ECT (Aksay et al., 2016). Improvement of depressive symptoms severity negatively correlated with an increase in HDL (Aksay et al., 2016).

Taken together, a growing body of evidence suggests that blood metabolic parameters are involved in the pathogenesis of MDD. Crucially, in line with our findings, serum cholesterol levels have been suggested as indicator to predict response to antidepressant treatment (Aksay et al., 2016; Wagner et al., 2019). Thus, understanding the relationship between cholesterol levels, such as LDL, and treatment response may be valuable to improve personalized treatments in DTD.

In our sample, lower BMI was associated with improvement of depressive symptoms following VNS. Previous studies demonstrated an association between BMI and major depressive

disorders (Kraus et al., 2023; Nour et al., 2023; Siau et al., 2025; L. Zhang et al., 2024). Crucially, the BMI has been suggested a major factor associated with the development of treatment resistant depression, with this association being even stronger in female individuals suffering from MDD (Karageorgiou et al., 2023). In the present study, the mean BMI was 30.1 (6.9), with 80% of the individuals enrolled were overweight with nearly half of the sample were obese. Particularly noteworthy, a bidirectional link between MDD and increased BMI has been stated, indicating that individuals with MDD are more likely to have an elevated BMI, and vice versa. Results on the relationship between VNS and BMI are inconclusive. In a paediatric sample including twenty-three individuals with epilepsy treated with VNS, no changes in BMI were observed after four years of treatment (Kansagra et al., 2010). On the other hand, in fourteen individuals with MDD, VNS was associated with weight loss after two years of treatment. In this sample, BMI and weight loss were positively correlated. However, no association was found between weight loss and improvement of depressive symptoms. An association between baseline BMI and treatment response has not been investigated (Pardo et al., 2007). Thus, further research is needed to elucidate the relationship between BMI and VNS treatment response.

Limitations

There are several limitations that should be stated. Antidepressant medication, such as Serotonin-Reuptake-Inhibitors and Tricyclic Antidepressants have been suggested to increase QTc intervals (Beach et al., 2014; Keshtkar et al., 2025). Moreover, neuroleptic medication, often used as augmentation strategy to improve antidepressant treatment has been associated with QTc prolongation (Bordet et al., 2023; Moeller et al., 2007). In this study, we missed to take psychotropic medication as a confounding factor into account. We investigated the association between QTc length and depressive symptoms reduction in a sample of forty-nine individuals. However, with several possible confounders we still have a relatively small sample size. Especially for the exploratory analysis of hematological makers the sample size is even smaller. Thus, an analysis of predictive markers would be valuable in a larger sample. In our sample, no ECG measurements were taken after VNS treatment initiation. Therefore, a possible effect of VNS on QTc length cannot be evaluated. A control group was not recruited. Additionally, we missed to evaluate physical activity that is suggested to alter immune cell counts (Guo et al., 2024). We further failed to evaluate criteria related to metabolic syndrome that have been linked to treatment resistant depression, such as hypertension and waist circumference (Meng et al., 2025). We measured serum lipids, and serum glucose, however, we missed to check for medication prescription for elevated TGs or hyperglycemia (Meng et al., 2025).

Conclusion

We could not replicate previous findings suggesting the QTc length as a predictive marker for VNS treatment response. However, our findings suggest a significant association between BMI, LDL,

absolute neutrophil count and reduction of depression severity in individuals treated with VNS adjunctive to treatment as usual. Our results emphasize the potential role of blood peripheral and anthropometric markers in the heterogeneity of depression and treatment response in individuals with DTD. Together, the predictors identified indicate a multifactorial interaction between inflammatory and metabolic markers in response to VNS. Further basic and prospective studies are needed to validate these findings and clarify the underlying mechanisms. Such studies will provide a basis for personalized interventions in individuals with DTD.

Declaration of competing interest

BTB received speaker/consultation fees from: AstraZeneca, Lundbeck, Pfizer, Takeda, Servier, Bristol Myers Squibb, Otsuka, LivaNova, Biogen, Angelini, Boehringer_Ingelheim and Janssen-Cilag. CK received speaker and advisor honoraria from Janssen–Cilag, Boeringer Ingelheim, Pfizer, AbbVie and travel grants from Roche, Pfizer and AOP Orphan. CRL received speaker and advisor honoraria from Janssen-Cilag, Medice and LivaNova. EK received speaker and advisor honoraria from LivaNova and Janssen-Cilag. All other authors declare that they have no competing interest.

Data availability

Data are available from the corresponding author upon reasonable request.

References

Aaronson, S. T., Sears, P., Ruvuna, F., Bunker, M., Conway, C. R., Dougherty, D. D., Reimherr, F. W., Schwartz, T. L., & Zajecka, J. M. (2017). A 5-Year Observational Study of Patients With Treatment-Resistant Depression Treated With Vagus Nerve Stimulation or Treatment as Usual: Comparison of Response, Remission, and Suicidality. *The American Journal of Psychiatry*, *174*(7), 640–648. https://doi.org/10.1176/APPI.AJP.2017.16010034

Aksay, S. S., Bumb, J. M., Janke, C., Biemann, R., Borucki, K., Lederbogen, F., Deuschle, M., Sartorius, A., & Kranaster, L. (2016). Serum lipid profile changes after successful treatment with electroconvulsive therapy in major depression: A prospective pilot trial. *Journal of Affective Disorders*, *189*, 85–88. https://doi.org/10.1016/J.JAD.2015.09.037

Amos, T. B., Tandon, N., Lefebvre, P., Pilon, D., Kamstra, R. L., Pivneva, I., & Greenberg, P. E. (2018). Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression: A Matched-Cohort Study Using a US Commercial Claims Database. *The Journal of Clinical Psychiatry*, *79*(2). https://doi.org/10.4088/JCP.17M11725

Beach, S. R., Kostis, W. J., Celano, C. M., Januzzi, J. L., Ruskin, J. N., Noseworthy, P. A., & Huffman, J. C. (2014). Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. *The Journal of Clinical Psychiatry*, *75*(5). https://doi.org/10.4088/JCP.13R08672

Bergfeld, I. O., Mantione, M., Figee, M., Schuurman, P. R., Lok, A., & Denys, D. (2018). Treatment-resistant depression and suicidality. *Journal of Affective Disorders*, *235*, 362–367. https://doi.org/10.1016/J.JAD.2018.04.016

Bordet, C., Garcia, P., Salvo, F., Touafchia, A., Galinier, M., Sommet, A., & Montastruc, F. (2023). Antipsychotics and risk of QT prolongation: a pharmacovigilance study. *Psychopharmacology*, *240*(1), 199–202. https://doi.org/10.1007/S00213-022-06293-4

C Bazett, B. H. (1997). AN ANALYSIS OF THE TIME-RELATIONS OF ELECTROCARDIOGRAMS. *Annals of Noninvasive Electrocardiology*, *2*(2), 177–194. https://doi.org/10.1111/J.1542-474X.1997.TB00325.X

Chen, J., Hua, S., Huang, L., Zhang, X., Yao, W., & Xue, Z. (2025). Exploring sedentary behavior, neutrophil-to-lymphocyte ratio, and depression: Mediation analysis in NHANES. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, *136*. https://doi.org/10.1016/J.PNPBP.2024.111140

Conway, C. R., Aaronson, S. T., Sackeim, H. A., Duffy, W., Stedman, M., Quevedo, J., Allen, R. M., Riva-Posse, P., Berger, M. A., Alva, G., Malik, M. A., Dunner, D. L., Cichowicz, I., Luing, H., Zajecka, J., Nahas, Z., Mickey, B. J., Kablinger, A. S., Kriedt, C. L., … Rush, A. J. (2024). Clinical characteristics and treatment exposure of patients with marked treatment-resistant unipolar major depressive disorder: A RECOVER trial report. *Brain Stimulation*, *17*(2), 448–459. https://doi.org/10.1016/J.BRS.2024.03.016

Conway, C. R., Aaronson, S. T., Sackeim, H. A., George, M. S., Zajecka, J., Bunker, M. T., Duffy, W., Stedman, M., Riva-Posse, P., Allen, R. M., Quevedo, J., Berger, M., Alva, G., Malik, M. A., Dunner, D. L., Cichowicz, I., Banov, M., Manu, L., Nahas, Z., … Rush, A. J. (2024). Vagus nerve stimulation in treatment-resistant depression: A one-year, randomized, sham-controlled trial. *Brain Stimulation*. https://doi.org/10.1016/J.BRS.2024.12.1191

Corcoran, C., Connor, T. J., O'Keane, V., & Garland, M. R. (2005). The effects of vagus nerve stimulation on pro- and anti-inflammatory cytokines in humans: a preliminary report. *Neuroimmunomodulation*, *12*(5), 307–309. https://doi.org/10.1159/000087109

Demyttenaere, K., Costa, T., Kavakbasi, E., Jiang, M., Scheltens, A., Dibué, M., Hall, B. E., Andrade, P., McAllister-Williams, R. H., Baune, B. T., & Young, A. H. (2024). Baseline characteristics of a European patient population with difficult-to-treat depression (RESTORE-LIFE) treated with adjunctive vagus nerve stimulation. *Journal of Affective Disorders*, *344*, 284–291. https://doi.org/10.1016/J.JAD.2023.10.054

Elbakary, N., Al-Khuzaei, N., Hussain, T., Karawia, A., Smida, M., Abu-Rahma, N., Akel, F., Mahmoud, S. E., Currie, J., Khoodoruth, M. A. S., & Ouanes, S. (2025). Inflammatory biomarkers as predictors for unlocking antidepressant efficacy: Assessing predictive value and risk stratification in major depressive disorder in a prospective longitudinal study. *Journal of Affective Disorders*, *387*. https://doi.org/10.1016/J.JAD.2025.119545

Foley, É. M., Parkinson, J. T., Mitchell, R. E., Turner, L., & Khandaker, G. M. (2023). Peripheral blood cellular immunophenotype in depression: a systematic review and meta-analysis. *Molecular Psychiatry*, *28*(3), 1004–1019. https://doi.org/10.1038/S41380-022-01919-7

Gabriel, A. (2007). Changes in plasma cholesterol in mood disorder patients: Does treatment make a difference? *Journal of Affective Disorders*, *99*(1–3), 273–278. https://doi.org/10.1016/J.JAD.2006.08.015

Giudicessi, J. R., Noseworthy, P. A., & Ackerman, M. J. (2019). The QT Interval. *Circulation*, *139*(24), 2711–2713. https://doi.org/10.1161/CIRCULATIONAHA.119.039598

Guo, Z., Xie, Z., Wang, P., Li, S., Xin, X., & Wang, X. (2024). The moderating effect of physical activity on the relationship between neutrophil count and depressive symptoms. *Scientific Reports*, *14*(1). https://doi.org/10.1038/S41598-024-63432-X

Hummel, J., Westphal, S., Weber-Hamann, B., Gilles, M., Lederbogen, F., Angermeier, T., Luley, C., Deuschle, M., & Kopf, D. (2011). Serum lipoproteins improve after successful pharmacologic antidepressant treatment: a randomized open-label prospective trial. *The Journal of Clinical Psychiatry*, *72*(7), 885–891. https://doi.org/10.4088/JCP.09M05853BLU

Jandackova, V. K., Britton, A., Malik, M., & Steptoe, A. (2016). Heart rate variability and depressive symptoms: a cross-lagged analysis over a 10-year period in the Whitehall II study. *Psychological Medicine*, *46*(10), 2121–2131. https://doi.org/10.1017/S003329171600060X

Jayanthi, R., Girijasivam, S. P., & Gaur, A. (2021). Association of blood pressure and BMI to corrected QT interval in young adults. *Canadian Journal of Physiology and Pharmacology*, *99*(9), 894–899. https://doi.org/10.1139/CJPP-2020-0520

Kansagra, S., Ataya, N., Lewis, D., Gallentine, W., & Mikati, M. A. (2010). The effect of vagus nerve stimulation therapy on body mass index in children. *Epilepsy & Behavior : E&B*, *19*(1), 50–51. https://doi.org/10.1016/J.YEBEH.2010.06.012

Karageorgiou, V., Casanova, F., O'Loughlin, J., Green, H., McKinley, T. J., Bowden, J., & Tyrrell, J. (2023). Body mass index and inflammation in depression and treatment-resistant depression: a Mendelian randomisation study. *BMC Medicine*, *21*(1). https://doi.org/10.1186/S12916-023-03001-7

Kavakbasi, E., Kraus, C., Reif-Leonhard, C., Blackwell, J. M., Dibué, M., Treiber, M., Achten, S., & Baune, B. T. (2025). Titration of vagus nerve stimulation for difficult-to-treat depression and onset of response: Early insights from the RESTORE-LIFE study. *Journal of Affective Disorders*, *378*, 39–46. https://doi.org/10.1016/J.JAD.2025.02.047

Kavakbasi, E., Van Assche, E., Schwarte, K., Hohoff, C., & Baune, B. T. (2024). Long-Term Immunomodulatory Impact of VNS on Peripheral Cytokine Profiles and Its Relationship with Clinical Response in Difficult-to-Treat Depression (DTD). *International Journal of Molecular Sciences*, *25*(8). https://doi.org/10.3390/IJMS25084196

Keshtkar, F., Zangeneh, S., Farjam, M., Fakhraei, B., Tabrizi, R., Dehghan, A., & Jafari, N. (2025). Electrocardiographic changes associated with SSRI use: Insights from a cross-sectional study in Fasa Adults Cohort Study (FACS). *Journal of Electrocardiology*, *91*. https://doi.org/10.1016/J.JELECTROCARD.2025.153932

Kofod, J., Elfving, B., Nielsen, E. H., Mors, O., & Köhler-Forsberg, O. (2022). Depression and inflammation: Correlation between changes in inflammatory markers with antidepressant response and long-term prognosis. *European Neuropsychopharmacology : The Journal of the European College of Neuropsychopharmacology*, *54*, 116–125. https://doi.org/10.1016/J.EURONEURO.2021.09.006

Kraus, C., Kautzky, A., Watzal, V., Gramser, A., Kadriu, B., Deng, Z. De, Bartova, L., Zarate, C. A., Lanzenberger, R., Souery, D., Montgomery, S., Mendlewicz, J., Zohar, J., Fanelli, G., Serretti, A., & Kasper, S. (2023). Body mass index and clinical outcomes in individuals with major depressive disorder: Findings from the GSRD European Multicenter Database. *Journal of Affective Disorders*, *335*, 349–357. https://doi.org/10.1016/J.JAD.2023.05.042

Kuang, D., Cui, L., Kuang, S., Yang, R., Chen, X., Zhang, L., Lv, R., Ou, S., & Song, C. (2019). Effect of gender-related depression on heart rate variability during an autonomic nervous test. *Psychiatry Research*, *272*, 258–264. https://doi.org/10.1016/J.PSYCHRES.2018.12.099

Lespérance, P., Desbeaumes Jodoin, V., Drouin, D., Racicot, F., Miron, J. P., Longpré-Poirier, C., Fournier-Gosselin, M. P., Thebault, P., Lapointe, R., Arbour, N., & Cailhier, J. F. (2024). Vagus Nerve Stimulation Modulates Inflammation in Treatment-Resistant Depression Patients: A Pilot

Study. *International Journal of Molecular Sciences*, *25*(5). https://doi.org/10.3390/IJMS25052679

Longpré-Poirier, C., Desbeaumes Jodoin, V., Miron, J. P., Fournier-Gosselin, M. P., & Lespérance, P. (2020). Electrocardiogram Corrected Q-T Interval Predicts Response to Vagus Nerve Stimulation in Depression. *The Journal of ECT*, *36*(4), 285–290. https://doi.org/10.1097/YCT.0000000000000684

McAllister-Williams, R. H., Arango, C., Blier, P., Demyttenaere, K., Falkai, P., Gorwood, P., Hopwood, M., Javed, A., Kasper, S., Malhi, G. S., Soares, J. C., Vieta, E., Young, A. H., Papadopoulos, A., & Rush, A. J. (2020). The identification, assessment and management of difficult-to-treat depression: An international consensus statement. *Journal of Affective Disorders*, *267*, 264–282. https://doi.org/10.1016/J.JAD.2020.02.023

Meng, X., Han, L., Fu, J., Hu, C., & Lu, Y. (2025). Associations between metabolic syndrome and depression, and the mediating role of inflammation: Based on the NHANES database. *Journal of Affective Disorders*, *375*, 214–221. https://doi.org/10.1016/J.JAD.2025.01.108

Moeller, O., Evers, S., Deckert, J., Baune, B. T., Dannlowski, U., Nguyen, D. H., Arolt, V., & Hetzel, G. (2007). The impact of ziprasidone in combination with sertraline on visually-evoked event-related potentials in depressed patients with psychotic features. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, *31*(7), 1440–1443. https://doi.org/10.1016/J.PNPBP.2007.06.021

Moretta, T., & Messerotti Benvenuti, S. (2022). Early indicators of vulnerability to depression: The role of rumination and heart rate variability. *Journal of Affective Disorders*, *312*, 217–224. https://doi.org/10.1016/J.JAD.2022.06.049

Ninla-aesong, P., Kietdumrongwong, P., Neupane, S. P., Puangsri, P., Jongkrijak, H., Chotipong, P., & Kaewpijit, P. (2024). Relative value of novel systemic immune-inflammatory indices and classical hematological parameters in predicting depression, suicide attempts and treatment response. *Scientific Reports*, *14*(1). https://doi.org/10.1038/S41598-024-70097-Z

Nour, M. O., Hafiz, T. A., & Alharbi, K. K. (2023). Measuring the relationship between body mass index and depression among Saudi adult population: A nationwide cross-sectional study. *PloS One*, *18*(11). https://doi.org/10.1371/JOURNAL.PONE.0293799

Osimo, E. F., Baxter, L. J., Lewis, G., Jones, P. B., & Khandaker, G. M. (2019). Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. *Psychological Medicine*, *49*(12), 1958–1970. https://doi.org/10.1017/S0033291719001454

Pardo, J. V., Sheikh, S. A., Kuskowski, M. A., Surerus-Johnson, C., Hagen, M. C., Lee, J. T., Rittberg, B. R., & Adson, D. E. (2007). Weight loss during chronic, cervical vagus nerve stimulation in depressed patients with obesity: an observation. *International Journal of Obesity (2005)*, *31*(11), 1756–1759. https://doi.org/10.1038/SJ.IJO.0803666

Persons, J. E., & Fiedorowicz, J. G. (2016). Depression and serum low-density lipoprotein: A systematic review and meta-analysis. *Journal of Affective Disorders*, *206*, 55–67. https://doi.org/10.1016/J.JAD.2016.07.033

Pigato, G., Rosson, S., Bresolin, N., Toffanin, T., Sambataro, F., Olivo, D., Perini, G., Causin, F., Denaro, L., Landi, A., & D'Avella, D. (2023). Vagus Nerve Stimulation in Treatment-Resistant Depression: A Case Series of Long-Term Follow-up. *The Journal of ECT*, *39*(1), 23–27. https://doi.org/10.1097/YCT.0000000000000869

Rush, A. J., Conway, C. R., Aaronson, S. T., George, M. S., Riva-Posse, P., Dunner, D. L., Zajecka, J., Bunker, M. T., Quevedo, J., Allen, R. M., Alva, G., Luing, H., Nahas, Z., Manu, L., Bennett, J. I., Mickey, B. J., Becker, J., Sheline, Y., Cusin, C., … Sackeim, H. A. (2024). Effects of vagus nerve stimulation on daily function and quality of life in markedly treatment-resistant major depression: Findings from a one-year, randomized, sham-controlled trial. *Brain Stimulation*. https://doi.org/10.1016/J.BRS.2024.12.1187

Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., McGrath, P. J., Rosenbaum, J. F., Sackeim, H. A., Kupfer, D. J., Luther, J., & Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. *The American Journal of Psychiatry*, *163*(11), 1905–1917. https://doi.org/10.1176/AJP.2006.163.11.1905

Šagud, M., Madžarac, Z., Nedic Erjavec, G., Šimunović Filipčić, I., Mikulić, F. L., Rogić, D., Bradaš, Z., Bajs Janović, M., & Pivac, N. (2023). The Associations of Neutrophil–Lymphocyte, Platelet–

Lymphocyte, Monocyte–Lymphocyte Ratios and Immune-Inflammation Index with Negative Symptoms in Patients with Schizophrenia. *Biomolecules*, *13*(2). https://doi.org/10.3390/BIOM13020297

Sforzini, L., Marizzoni, M., Bottanelli, C., Kunšteková, V., Zonca, V., Saleri, S., Kose, M., Lombardo, G., Mariani, N., Nettis, M. A., Nikkheslat, N., Worrell, C., Zajkowska, Z., Pointon, L., Cowen, P. J., Cavanagh, J., Harrison, N. A., Riva, M. A., Mondelli, V., … Pariante, C. M. (2025). Transcriptomic profiles in major depressive disorder: the role of immunometabolic and cell-cycle-related pathways in depression with different levels of inflammation. *Molecular Psychiatry*, *30*(4), 1308–1318. https://doi.org/10.1038/S41380-024-02736-W

Siau, C. S., Lester, D., Lew, B., Kõlves, K., Huen, J. M. Y., Gunn, J. F., Sun Chen, W., Ibrahim, N., Fariduddin, M. N., Koo, H. C., Jia, C., Prawiromaruto, I. G., & Chan, C. M. H. (2025). Association Between Body Mass Index and Depression, Anxiety, and Suicidality in University Students From Seven Regions of China: A Cross-Sectional Study. *Asia-Pacific Journal of Public Health*, *37*(2–3), 281–289. https://doi.org/10.1177/10105395241311134

Singh, D., Guest, P. C., Dobrowolny, H., Vasilevska, V., Meyer-Lotz, G., Bernstein, H. G., Borucki, K., Neyazi, A., Bogerts, B., Jacobs, R., & Steiner, J. (2022). Changes in leukocytes and CRP in different stages of major depression. *Journal of Neuroinflammation*, *19*(1). https://doi.org/10.1186/S12974-022-02429-7

Singh, I., & Rabkin, S. W. (2021). Circadian variation of the QT interval and heart rate variability and their interrelationship. *Journal of Electrocardiology*, *65*, 18–27. https://doi.org/10.1016/J.JELECTROCARD.2021.01.004

Wagner, C. J., Musenbichler, C., Böhm, L., Färber, K., Fischer, A. I., von Nippold, F., Winkelmann, M., Richter-Schmidinger, T., Mühle, C., Kornhuber, J., & Lenz, B. (2019). LDL cholesterol relates to depression, its severity, and the prospective course. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, *92*, 405–411. https://doi.org/10.1016/J.PNPBP.2019.01.010

Watanabe, D. K., Jarczok, M. N., Williams, D. W. P., Koenig, J., & Thayer, J. F. (2024). Evaluation of low vagally-mediated heart rate variability as an early marker of depression risk. *Journal of Affective Disorders*, *365*, 146–154. https://doi.org/10.1016/J.JAD.2024.08.051

Xue, L., Lewis, E., Bocharova, M., Young, A. H., & Aarsland, D. (2025). Decreased neutrophil-to-lymphocyte ratio predicted cognitive improvement in late-life depression treated with vortioxetine: Findings from an eight-week randomized controlled trial. *Brain, Behavior, and Immunity*, *126*, 53–58. https://doi.org/10.1016/J.BBI.2025.01.029

Zhang, L., Wang, Z., Liu, K., Li, J., & Li, Y. (2024). Investigation of the relationship between heavy metals in the blood and depression in people with different body mass indices using the NHANES database: A cross-sectional study. *Journal of Affective Disorders*, *344*, 311–318. https://doi.org/10.1016/J.JAD.2023.10.023

Zhang, X., Guo, Y. M., Ning, Y. P., Cao, L. P., Rao, Y. H., Sun, J. Q., Qing, M. J., & Zheng, W. (2022). Adjunctive vagus nerve stimulation for treatment-resistant depression: a preliminary study. *International Journal of Psychiatry in Clinical Practice*, *26*(4), 337–342. https://doi.org/10.1080/13651501.2021.2019789

Zheng, Y., Yin, K., Li, L., Wang, X., Li, H., Li, W., & Fang, Z. (2024). Association between immune-inflammation-based prognostic index and depression: An exploratory cross-sectional analysis of NHANES data. *Journal of Affective Disorders*, *362*, 75–85. https://doi.org/10.1016/J.JAD.2024.06.103